Boston Scientific agreed to acquire medical device company Penumbra in a cash-and-stock deal valued at approximately $14.5 billion, marking its largest acquisition in two decades. The acquisition will expand Boston Scientific's cardiovascular and vascular medicine business by adding Penumbra's thrombectomy systems. Following the announcement, Boston Scientific's stock fell 4.6% in afternoon trading, while Penumbra's stock jumped over 12%. The deal is expected to close later this year.